Aceragen Retained Earnings (Accumulated Deficit) 2010-2023 | ACGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aceragen retained earnings (accumulated deficit) from 2010 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Aceragen Retained Earnings (Accumulated Deficit) 2010-2023 | ACGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Aceragen retained earnings (accumulated deficit) from 2010 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.4B
Gilead Sciences (GILD)	$121.9B
Bristol Myers Squibb (BMY)	$111B
CSL (CSLLY)	$91.9B
Regeneron Pharmaceuticals (REGN)	$90.6B
GSK (GSK)	$76B
Argenex SE (ARGX)	$35.4B
Alnylam Pharmaceuticals (ALNY)	$35.1B
BioNTech SE (BNTX)	$25.7B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.6B
BeiGene (BGNE)	$20.1B
Moderna (MRNA)	$19.3B
Incyte (INCY)	$15.9B
Genmab (GMAB)	$15.3B
Insmed (INSM)	$12.8B
Vaxcyte (PCVX)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.5B
Exelixis (EXEL)	$10.2B
QIAGEN (QGEN)	$10.1B
Revolution Medicines (RVMD)	$9.9B
Exact Sciences (EXAS)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.1B
Ascendis Pharma (ASND)	$7.7B